Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-ht7/5-ht1a receptor selectivity

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2384-2392

  Medina, Rocío A ^a   Sallander, Jessica ^b   Benhamú, Bellinda ^a   Porras, Esther ^a,c   Campillo, Mercedes ^b   Pardo, Leonardo ^b   López Rodríguez, María L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; ISOQUINOLINE DERIVATIVE; LIGAND; OXINDOLE; PARTIAL AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UCM 5600; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR MODEL; PHARMACOPHORE; RECEPTOR AFFINITY;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; DRUG PARTIAL AGONISM; HUMANS; INDOLES; ISOQUINOLINES; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249142641     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8014553     Document Type: Article

References (49)

1. Nichols, D. E.; Nichols, C. D. Serotonin receptors. Chem. Rev. 2008, 108, 1614-1641.
2. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-554.
3. Lydiard, R. B. An overview of generalized anxiety disorder: disease state-appropriate therapy. Clin. Ther. 2000, 22 (Suppl. A), A3-19.
4. Visser, W. H.; de Vriend, R. H.; Jaspers, M. W.; Ferrari, M. D. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996, 47, 46-51.
5. Mine, R. J.; Heel, R. C. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991, 41, 574-595.
6. 7 receptor research. Trends Pharmacol. Sci. 2004, 25, 481-486.
7. Thomas, D. R.; Hagan, J. J. 5-HT7 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 81-90.
8. Plassat, J. L.; Amlaiky, N; Hen, R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol. Pharmacol. 1993, 44, 229-236.
9. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 8547-8551.
10. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993, 11, 449-458.
11. 7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 2002, 42, 74-81.
12. 7 receptor knockout mice: 5-HT and 8-OH-DPAT-induced phase advances of SCN neuronal firing. J. Biol. Rhythms 2005, 20, 122-131.
13. 7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol. Psychiatry 2005, 58, 831-837.
14. Roberts, A. J.; Krucker, T.; Levy, C. L.; Slanina, K. A.; Sutcliffe, J. G.; Hedlund, P. B. Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur. J. Neurosci. 2004, 19, 1913- 1922.
15. 7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol. 1999, 127, 609-616.
16. Prins, N. H.; Briejer, M. R.; Van Bergen, P. J.; Akkermans, L. M.; Schuurkes, J. A. Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle. Br. J. Pharmacol. 1999, 128, 849-852.
17. Terron, J. A. Is the 5-HT (7) receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. 2002, 439, 1-11.
18. De Ponti, F.; Tonini, M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001, 61, 317-332.
19. Lovell, P. J.; Bromidge, S. M.; Dabbs, S.; Duckworth, D. M.; Forbes, I. T.; Jennings, A. J.; King, F. D.; Middlemiss, D. N.; Rahman, S. K.; Saunders, D. V.; Collin, L. L.; Hagan, J. J.; Riley, G. J.; Thomas, D. R. A novel, potent, and selective 5-HT (7) antagonist: (R) -3- (2- (2- (4-methylpiperidin-1- yl) ethyl) pyrrolidine-1-sulfonyl) phenol (SB-269970). J. Med. Chem. 2000, 43, 342-345.
20. 7 receptor antagonists. Bioorg. Med. Chem. Lett 2003, 13, 1055-1058.
21. Kikuchi, C.; Suzuki, H.; Hiranuma, T.; Koyama, M. New tetrahy-drobenzindoles as potent and selective 5-HT (7) antagonists with increased in vitro metabolic stability. Bioorg. Med. Chem. Lett. 2003, 13, 61-64.
22. Leopoldo, M.; Berardi, F.; Colabufo, N. A.; Contino, M.; Lacivita, E.; Niso, M.; Perrone, R.; Tortorella, V. Structure-affinity relationship study on N- (1, 2, 3, 4-tetrahydronaphthalen-1-yl) -4-aryl-1-piperazinealky- lamides, a new class of 5-hydroxytryptamine7 receptor agents. J. Med. Chem. 2004, 47, 6616-6624.
23. López-Rodríguez, M. L.; Porras, E.; Benhamú, B.; Ramos, J. A.; Morcillo, M. J.; Lavandera, J. L. First pharmacophoric hypothesis for 5-HT7 antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
24. Lopez-Rodríguez, M. L.; Porras, E.; Morcillo, M. J.; Benhamú, B.; Soto, L. J.; Lavandera, J. L.; Ramos, J. A.; Olivella, M.; Campillo, M.; Pardo, L. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naph-thosultam derivatives. J. Med. Chem. 2003, 46, 5638-5650.
25. Vermeulen, E. S.; Schmidt, A. W.; Sprouse, J. S.; Wikstrom, H. V.; Grol, C. J. Characterization of the 5-HT (7) receptor. Determination of the pharmacophore for 5-HT (7) receptor agonism and CoMFA-based modeling of the agonist binding site. J. Med. Chem. 2003, 46, 5365-5374.
26. 7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1, 2, 3, 4-tetrahydroisoquinoline-based arylsulfonamides. J. Med. Chem. 2004, 47, 5451-5466.
27. Kolaczkowski, M.; Nowak, M.; Pawlowski, M.; Bojarski, A. J. Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity. J. Med. Chem. 2006, 49, 6732-6741.
28. 2 receptor antagonists: potential atypical antipsychotic agents. J. Med. Chem. 1994, 37, 2552-2563.
29. Nishiyama, M.; Yamamoto, T.; Koie, Y. Synthesis of N- arylpiperazines from aryl halides and piperazine under a palladium tri-tert-butylphos-phine catalyst. Tetrahedron Lett. 1998, 39, 617-620.
30. López-Rodriguez, M. L.; Benhamu, B.; Ayala, D.; Rominguera, J. L.; Murcia, M.; Ramos, J. A.; Viso, A. Pd (0) amination of benzimidazoles as an efficient method towards new (benzimidazolyl) piperazines with high affinity for the 5-HT (1A) receptor. Tetrahedron 2000, 56, 3245-3253.
31. Gauthier, S.; Cloutier, J.; Dory, Y. L.; Favre, A.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Merand, Y.; Martel, C.; Simard, J.; Labrie, F. Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. J. Enzyme Inhib. Med. Chem. 2005, 20, 165-177.
32. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
33. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
34. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454, 486-91.
35. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
36. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318, 1266-1273.
37. Smit, M. J.; Vischer, H. F.; Bakker, R. A.; Jongejan, A.; Timmerman, H; Pardo, L.; Leurs, R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 53-87.
38. 1A receptor affinity in the group of long-chain arylpiperazine ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5863-5866.
39. Adham, N.; Zgombick, J. M.; Bard, J.; Branchek, T. A. Functional characterization of the recombinant human 5-hydroxytryptamine7 (a) receptor isoform coupled to adenylate cyclase stimulation. J. Phar-macol. Exp. Ther. 1998, 287, 508-514.
40. Schwartz, T. W.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Elling, C. E. Molecular mechanism of 7TM receptor activation--a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 481-519.
41. Jongejan, A.; Bruysters, M.; Ballesteros, J. A.; Haaksma, E.; Bakker, R. A.; Pardo, L.; Leurs, R. Linking agonist binding to histamine H1 receptor activation. Nat. Chem. Biol. 2005, 1, 98-103.
42. López-Rodríguez, M. L.; Morcillo, M. J.; Fernández, E.; Benhamú, B.; Tejada, I.; Ayala, D.; Viso, A.; Campillo, M.; Pardo, L.; Delgado, M.; Manzanares, J.; Fuentes, J. A. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT (1A) R agonists with selectivity over alpha1-adrenoceptors. J. Med. Chem. 2005, 48, 2548-58.
43. Boar, B. R.; O'Shea, D. M.; Tomlinson, I. D. 1-Substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase. PCT Int. Appl. WO 94/29272, 1994.
44. Canutescu, A. A.; Shelenkov, A. A.; Dunbrack, R. L. Jr. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 2003, 12, 2001-2014.
45. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
46. Pardo, L.; Deupí, X.; Dolker, N.; López-Rodríguez, M. L.; Campillo, M. The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. ChemBioChem 2007, 8, 19-24.
47. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 2003, 24, 1999-2012.
48. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, 1157-1174.
49. Case, D. A.; Darden, T. A.; Cheatham, T. E. I.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D. H; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER 9; University of California: San Francisco, 2006.